A genetically engineered microorganism for the production of a cannabinoid is described. The genetically engineered microorganism comprises at least one nucleic acid molecule encoding at least one cannabinoid biosynthetic pathway enzyme. The disclosure also relates to methods for producing a cannabinoid using a genetically engineered microorganism.

Synthetic cannabinoid compounds for treatment of pain and anxiety by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure:

##STR00001##

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.

The present disclosure relates to the production of cannabinoids in either recombinant microorganism or in cell-free systems using a combination of enzymes, including but not limited to a PKS enzyme, a npgA enzyme, a cs-OLAS-1, a pp-DVAS-1, a cs-HEX-1 and/or Butiryl synthase.

This document relates to using bidirectional, multi-enzymatic scaffolds to biosynthesize cannabinoids in recombinant hosts.

Described herein are variant, novel cannabinoid synthases, nucleic acids encoding same, and various uses thereof. In one aspect, a variant cannabinoid synthase or an active fragment thereof is provided comprising a non-naturally occurring amino acid sequence relative to a wild-type cannabinoid synthase or an active fragment thereof which acts on a substrate to produce an altered amount of a cannabinoid relative to an amount of the cannabinoid produced by the wild-type cannabinoid synthase or active fragment thereof.

Compositions and methods for providing desired cannabinoid content in cannabis plants. More particularly, the invention relates to compositions and methods for using cannabinoid synthase paralogs as guidance for breeding cannabis plants with a desired cannabinoid content, including but not limited to cultivars, varieties, lines and methods of breeding the same for commercial use.

The present invention relates generally to production methods, enzymes and recombinant yeast strains for the biosynthesis of clinically important cannabinoid compounds.

Synthetic cannabinoid compounds for treatment of epilepsy, substance addiction, and Alzheimer's disease by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure: ##STR00001##
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.

The present technology provides trichome specific promoters of cannabinoid biosynthesis enzyme genes from Cannabis, nucleotide sequences of the trichome specific promoters, and uses of the promoters for modulating the production of cannabinoids and other compounds in organisms. The present technology also provides chimeric genes, vectors, and transgenic cells and organisms, including plant cells and plants, comprising the trichome specific promoters. Also provided are methods for expressing nucleic acid sequences in cells and organisms using the trichome specific promoters.

Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.